Team:TMU-Tokyo/Safety/Questions

From 2013.igem.org

(Difference between revisions)
 
(3 intermediate revisions not shown)
Line 8: Line 8:
<html>
<html>
 +
<head>
 +
<style>
 +
  img{float:left;}
 +
</style>
 +
</head>
 +
 +
 
<body>
<body>
-
<!--<Br><Br>
+
<Br><Br>
<div class="container_12">
<div class="container_12">
  <div class"grid_12">
  <div class"grid_12">
-
  <h1>iGEM 2013 Basic Safety Form</h1>
+
  <h1>iGEM 2013 Basic Safety Form </h1>
-
  <Hr>
+
  <hr>
-
<br>
+
-
  <div class="grid_2">
+
-
  <p><b>Team name: </b></p>
+
-
  </div>
+
-
  <div class="grid_10">
+
-
  <table><tr><td><p>TMU-Tokyo</p></td></tr></table>
+
-
  </div>
+
-
<div class="clear"></div>
+
-
+
-
<div class="container_12">
+
-
<div class="grid_12">
+
-
  <b>
+
-
    <p>Deadline: 30th of August 2013<br><br></p>
+
-
    <p>Submission method: email form to the correct email list for your region:<br><br></p>
+
-
    <p>safety_forms_asia@igem.org<br></p>
+
-
    <p>safety_forms_europe@igem.org<br></p>
+
-
    <p>safety_forms_north_america@igem.org<br></p>
+
-
    <p>safety_forms_latin_america@igem.org<br></p>
+
-
  </b>
+
-
  <br>
+
-
  <p>Students can complete this safety form, but it must be read and signed (electronic or hard copy) by your team's
+
-
    faculty advisor. Your advisor must verify the information contained in this form and sign it.</p><br> 
+
-
  <p>The iGEM Safety Committee must be able to easily reach the advisor with questions or other follow-up
+
-
    communication. If you have made changes to your project (new coding regions or organisms) you must resubmit your
+
-
    safety form before wiki freeze (date TBD).</p><br> 
+
-
  Key points to remember as you complete the safety assessment process: <br>
+
-
  <ul><li>    • For help in completing questions 1 and 2, you may find it useful to consult the Risk Groups section
+
-
                of the Safety Resources List [2013.igem.org/Safety]. </li>
+
-
      <li>    • The iGEM Safety Committee will be reviewing your project. To avoid temporary suspensions, answer
+
-
                these questions completely and accurately.  </li>
+
-
      <li>    • The Safety Committee needs to be able to communicate with your faculty advisor about any safety
+
-
                concerns. If we cannot reach your advisor in a reasonable amount of time, you may be subject to
+
-
                restrictions at the Jamboree. </li>
+
-
      <li>    • Your safety page, wiki project page and poster should be consistent with each other. If you change
+
-
                your project, submit an updated Basic Safety Page to the iGEM Safety Committee before the wiki
+
-
                freeze. (Your faculty advisor must also read and sign the updated page.) </li>
+
-
      <li>    • We understand that projects may still be changing at a late date. However, large discrepancies
+
-
                between what you submit on the Basic Safety Page and what you present at the Jamborees may result in
+
-
                restrictions at the Jamboree.</li>
+
-
  </ul>
+
-
<div class="clear"></div>-->
+
-
<br><br><br>
+
<div class="container_12">
<div class="container_12">
-
<h1>Basic Safety Questions for iGEM 2013 </h1>
 
-
<hr><br>
 
-
<p>a. Please describe the chassis organism(s) you will be using for this project. If you will be using more than one
 
-
    chassis organism, provide information on each of them:  </p>
 
-
<p>
 
-
<table>
 
-
  <tr><td></td>
 
-
      <td>Species </td>
 
-
      <td>Strain no/name </td>
 
-
      <td>Risk Group</td>
 
-
      <td>Risk group source link </td>
 
-
      <td>Disease risk to humans? If so, which disease?</td>
 
-
  </tr>
 
-
  <tr><td>Ex </td>
 
-
      <td><i>E. coli</i> (K 12)  </td>
 
-
      <td>NEB 10 Beta </td>
 
-
      <td>1 </td>
 
-
      <td>www.absa.org/riskgroups/bacteria search.php?genus=&species=coli </td>
 
-
      <td>Yes. May cause
 
-
          irritation to skin, eyes, and respiratory tract, may affect kidneys.</td>
 
-
  </tr>
 
-
  <tr><td>1 </td>
 
-
      <td>E.coli (K-12)  </td>
 
-
      <td>MG1655 </td>
 
-
      <td>1 </td>
 
-
      <td><a href="www.atcc.org/products/all/700926.aspx">www.atcc.org/products/all/700926.aspx</a>  </td>
 
-
      <td>No.  </td>
 
-
  </tr>
 
-
  <tr><td>2 </td>
 
-
      <td>Bacteriophage </td>
 
-
      <td>P1 </td>
 
-
      <td>1 </td>
 
-
      <td><!--a href="http://www.absa.org/abj/abj/101501Verh eust.pdf"> http://www.absa.org/abj/abj/101501Verh eust.pdf</a>--></td>
 
-
      <td>No. </td>
 
-
  </tr>
 
-
  <tr><td>3 </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
  </tr>
 
-
  <tr><td>4 </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
  </tr>
 
-
  <tr><td>5 </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
  </tr>
 
-
  <tr><td>6 </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
  </tr>
 
-
  <tr><td>7 </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
  </tr>
 
-
  <tr><td>8 </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
      <td> </td>
 
-
  </tr>
 
-
</table>
 
-
</p>
 
-
<p>*For additional organisms, please include a spreadsheet in your submission. </p>
 
-
<br>
 
-
<p>2. Highest Risk Group Listed:</p>
 
 +
<div class="grid_1">
 +
<p><br></p>
 +
</div>
-
<br>
+
<div class="grid_11">
-
  <p> If you answered 1+, please also complete the iGEM Biosafety form part 2 for any organisms in this category.</p>
+
  <p>(These are thumbnails. Click an image, you watch PDF.) </p>
-
<p>3. List and describe all new or modified coding regions you will be using in your project. (If you use parts
+
</div>
-
    from the 2013 iGEM Distribution without modifying them, you do not need to list those parts.)</p>
+
-
<table>
+
-
  <tr><td> </td>
+
-
      <td>Part number. </td>
+
-
      <td>Where did you get the physical DNA for this part (which lab,
+
-
          synthesis company, etc) </td>
+
-
      <td>What species does this part originally come from?  </td>
+
-
      <td>What is the Risk Group of the species?  </td>
+
-
      <td>What is the function of this part, in its parent species?  </td>
+
-
  </tr>
+
-
  <tr><td>Ex </td>
+
-
      <td> BBa_C0040  </td>
+
-
      <td>Synthesized, Blue Heron  </td>
+
-
      <td>Acinetobacter baumannii </td>
+
-
      <td>2 </td>
+
-
      <td>Confers tetracycline resistance </td>
+
-
  </tr>
+
-
  <tr><td>1 </td>
+
-
      <td>BBa_K101 5000 </td>
+
-
      <td>Molecular genetics laboratory, Tokyo Metropolitan University  </td>
+
-
      <td>E.coli K-12 MG1655  </td>
+
-
      <td>1 </td>
+
-
      <td>replication of plasmid, reguration of  plasmid copy number</td>
+
-
  </tr>
+
-
  <tr><td>2 </td>
+
-
      <td>BBa_K101 5001</td>
+
-
      <td>Invitrogen </td>
+
-
      <td>E. coli K-12 MG1655  </td>
+
-
      <td>1 </td>
+
-
      <td>DNA-binding transcriptional dual regulator </td>
+
-
  </tr>
+
-
  <tr><td>3 </td>
+
-
      <td>BBa_K1015 005,K1015007</td>
+
-
      <td>Molecular  genetics laboratory , Tokyo Metropolitan University </td>
+
-
      <td>E. coli K-12 MG1655 </td>
+
-
      <td>1 </td>
+
-
      <td>transcriptional operon  </td>
+
-
  </tr>
+
-
  <tr><td>4 </td>
+
-
      <td>BBa_K1015 006,K1015007</td>
+
-
      <td>Molecular genetics laboratory, Tokyo Metropolitan University </td>
+
-
      <td>E. coli K-12 MG1655(by pSC101cloning vecter) </td>
+
-
      <td>1 </td>
+
-
      <td>tetracycline resistance </td>
+
-
  </tr>
+
-
  <tr><td>5 </td>
+
-
      <td>BBa_K101 5001 </td>
+
-
      <td>Molecular genetics laboratory, Tokyo Metropolitan University </td>
+
-
      <td>E. coli K-12 MG1655  </td>
+
-
      <td>1 </td>
+
-
      <td>repress pLac  </td>
+
-
  </tr>
+
-
  <tr><td>6 </td>
+
-
      <td>BBa_K101 5002 </td>
+
-
      <td>Molecular genetics laboratory, Tokyo Metropolitan University </td>
+
-
      <td>Tn9  </td>
+
-
      <td>1 </td>
+
-
      <td>Chloramphenicol resistance </td>
+
-
  </tr>
+
-
  <tr><td>7 </td>
+
-
      <td>BBa_K101 5002 </td>
+
-
      <td>Molecular genetics laboratory, Tokyo Metropolitan University </td>
+
-
      <td>Tn903 </td>
+
-
      <td>1 </td>
+
-
      <td>Kanamycin 　resistance </td>
+
-
  </tr>
+
-
  <tr><td>8 </td>
+
-
      <td>BBa_K101 5003 </td>
+
-
      <td>Molecular genetics laboratory, TMU </td>
+
-
      <td>pI208 from S.aureus </td>
+
-
      <td>2 </td>
+
-
      <td>Ampicillin resistance  </td>
+
-
  </tr>
+
-
</table>
+
-
<p>*For additional coding regions, please include a spreadsheet in your submission. </p>
+
-
<br>
+
-
<p>4. Do the biological materials used in your lab work pose any of the following risks? Please describe. </p>
+
<div class="clear"></div>
 +
 
 +
 
 +
<div class="container_12">
 +
 
 +
<div class="grid_1">
 +
<p><br></p>
 +
</div>
 +
<div class="grid_5">
 +
 
  <br>
  <br>
-
  <p>a. Risks to the safety and health of team members or others working in the lab? </p>
+
  <a href="https://static.igem.org/mediawiki/2013/a/a3/TMUBasic-safty-form.pdf">
-
<table><tr><td><p>In this year, we use E.coli(K-12) and P1 bacteriophage in our lab and they don't have any
+
    <img align="center"width="350"height="400" src="https://static.igem.org/mediawiki/2013/7/72/Basic-safety-form.jpg"></a>
-
                  risks to the safety and health of team members or others. </p></td></tr>
+
-
</table>  
+
-
<br>  
+
-
<p>b. Risks to the safety and health of the general public, if released by design or by accident? </p>
+
-
<table><tr><td><p>E.coli K-12 strain is harmless strain. They are part of the normal flora of the human guts. Also Bacteriophage P1 can't infection human cells. So If they are released, there're no danger to the
+
-
                general public. </p></td></tr>
+
-
</table>  
+
  <br>
  <br>
-
<p>c. Risks to the environment, if released by design or by accident? </p>
 
-
<table><tr><td><p>E.coli K-12 strain and bacteriophage P1 are generally in the natural world, so if they are
 
-
                  released to the outside, there aren't any danger or harmful effect. </p></td></tr>
 
-
</table>
 
  <br>
  <br>
-
<p>d. Risks to security through malicious misuse by individuals, groups, or countries? </p>
+
</div>
-
<table><tr><td><p>E.coli K-12 strain and bacteriophage P1 aren't dangerous creatures, so we think there isn't danger
+
-
                  in particular as far as they just use them. But If they use genetically modified E.coli or
+
-
                  bacteriophage P1 may have some risk. </p></td></tr>
+
-
</table>
+
-
<br><br><br>
+
-
+
-
+
-
+
-
<p>5. If your project moved from a small-scale lab study to become widely used as a commercial/industrial product,
+
-
        what new risks might arise? (Consider the different categories of risks that are listed in parts a-d of the
+
-
        previous question.) Also, what risks might arise if the knowledge you generate or the methods you develop
+
-
        became widely available? (Note: This is meant to be a somewhat open-ended discussion question.)  In our
+
-
        project, we use a lot of drug-resistant genes. So if our project moved from our lab to the outside,</p>
+
-
+
-
<table><tr><td><p>there might be the risk that some bacteria which are in the natural world come to have drug resistance because of horizontal transmission. </p></td></tr>
+
-
</table>
+
-
<Br>
+
-
<p>6. Does your project include any design features to address safety risks? (For example: kill switches, auxotrophic chassis, etc.) Note that including such features is not mandatory to participate in iGEM, but many groups choose to include them. </p>
+
<div class="grid_5">
-
<table><tr><td><p>Our project doesn't have  any design which address safety risks, for instance, apotosis system or
+
  <p><br></p>
-
                  kill switch. Our parts don't generate any harmful substance, so we think we don't have to design
+
   <a href="https://static.igem.org/mediawiki/2013/c/c0/TMUIGEM_Biosafety_Form_Part_2.pdf">
-
                  such systems in our project.</p></td></tr>
+
     <img width="350"height="400" src="https://static.igem.org/mediawiki/2013/0/0b/Safety-form2.jpg"></a>
-
</table>
+
</div>
-
<Br>
+
-
<p>7. What safety training have you received (or plan to receive in the future)?  Provide a brief description, 
+
-
        and  </p>
+
-
  <p>a link to your institution’s safety training requirements, if available. </p>
+
-
  <table><tr><td><p>We received safety training programs from our instructors and our university's biosafety
+
-
                    comittee. We learned about what we should be careful of in a safety aspect during an
+
-
                    experoment.For instance, they tought us how to handle dangerous drug or chemical substances.
+
-
                    Also, they helped us to make the safet</p></td></tr>
+
-
</table>
+
-
<Br>
+
-
<p>8. Under what biosafety provisions will / do you work? </p>
+
-
  <p>a. Please provide a link to your institution biosafety guidelines. <br>
+
-
  <table width="960"><tr><td>
+
-
<a href="http://www.se.tmu.ac.jp/jimu/1_syomu/201%20kenkyuuanzenrinri/1%20rinri%20kitei.pdf">
+
-
      http://www.se.tmu.ac.jp/jimu/1_syomu/201%20kenkyuuanzenrinri/1%20rinri%20kitei.pdf</a></p>
+
-
  </td></tr>
+
-
  </table>
+
-
<span style="line-height:30%"><Br></span>
+
-
+
-
  <p>b. Does your institution have an Institutional Biosafety Committee, or an equivalent group? If yes, have you
+
-
        discussed your project with them? Describe any concerns they raised with your project, and any changes you
+
-
        made to your project plan based on their review. </p>
+
-
<table width="960"><tr><td><p>Yes, there is a biosafety commitee in our university and we've discussed our project with them. Theysaid that there was no point which has a problem in a safety aspect. </p>
+
-
   <a href="http://www.biol.se.tmu.ac.jp/nenpo/nenpo2012.pdf">http://www.biol.se.tmu.ac.jp/nenpo/nenpo2012.pdf</a>           
+
-
      </td></tr></table>
+
-
<span style="line-height:30%"><Br></span>
+
-
<p>c. Does your country have national biosafety regulations or guidelines? If so, please provide a link to these
+
-
     regulations or guidelines if possible.
+
-
  <br><table width="960"><tr><td><a href="http://www.maff.go.jp/j/syouan/nouan/carta/c_data/pdf/law_97.pdf">
+
-
      http://www.maff.go.jp/j/syouan/nouan/carta/c_data/pdf/law_97.pdf</a></tr></td>
+
-
  </table>
+
-
<span style="line-height:30%"><Br></span>
+
-
<p>d. According to the WHO Biosafety Manual, what is the BioSafety Level rating of your lab? (Check the summary
+
-
    table on page 3, and the fuller description that starts on page 9.) If your lab does not fit neatly into category
+
-
    1, 2, 3, or 4, please describe its safety features [see 2013.igem.org/Safety for help]. </p>
+
-
    <table width="960"><tr><td>BS1<br></td></tr></table>
+
-
<span style="line-height:30%"><Br></span>  
+
<div class="clear"></div>
-
<P>e. What is the Risk Group of your chassis organism(s), as you stated in question 1? If it does not match the BSL
+
<br>
-
    rating of your laboratory, please explain what additional safety measures you are taking. </p>
+
-
<table><tr><td><p>The risk group of our chassis organism is group1. So our laboratry match the BSL rating.
+
-
If our laboratry does'nt match BSL rate, we must take many safety measures. </p></td></tr>
+
-
        <p>For example, we must provide ample space for the safe conduct of laboratory work and for cleaning and</p> </table>
+
-
<Br>
+
-
Faculty Advisor Name:
+
-
<table><tr><td><p>KIMIKO FUKUDA</p></td></tr>
+
-
</table>  
+
 +
<div class"grid_12">
   
   
-
Faculty Advisor Signature:
+
<h1 align="right">iGEM 2013 Biosafety Form Part2</h1>
-
<table><tr><td><img src="#"></td></tr>
+
<hr>  
-
  </table>  
+
 +
  <br>
 +
<br>
-
<p>
+
</div>
-
署名: KIMIKO FUKUDA (Aug 30, 2013)</p>
+
-
<p>電子メール: kokko@tmu.ac.jp</p> 
+
</body>
</body>
</html>
</html>

Latest revision as of 08:40, 25 September 2013




iGEM 2013 Basic Safety Form


(These are thumbnails. Click an image, you watch PDF.)







iGEM 2013 Biosafety Form Part2



Retrieved from "http://2013.igem.org/Team:TMU-Tokyo/Safety/Questions"